<DOC>
	<DOCNO>NCT02165813</DOCNO>
	<brief_summary>This multi-centre ( RDH ASH ) , phase IV , double-blind , randomise , placebo-controlled trial oral NTZ treatment acute gastroenteritis require admission hospital . Four hundred child age three month less five year age enrol . Study participation would point enrolment 60 day enrolment . Enrolment occur within 48 hour admission hospital . Enrolled participant randomise 1:1 Nitazoxanide ( NTZ ) placebo . Other treatment management per standard care describe admit hospital 's guideline ultimately decision responsibility name medical consultant . Stool sample collect point admission . Solicitation symptom review routinely collect medical data record participant 's medical record , supplement completion study specific diary card discharge . All participant follow day 7 enrolment ( telephone already discharge ) ascertain symptom occur intervening period . At day 30 60 enrolment clinical record review conduct participant ascertain health care attendance follow discharge .</brief_summary>
	<brief_title>Oral Nitazoxanide Acute Gastroenteritis Australian Indigenous Children</brief_title>
	<detailed_description>This multi-centre ( RDH ASH ) , phase IV , double-blind , randomise , placebo-controlled trial oral NTZ treatment acute gastroenteritis require admission hospital . Four hundred child age three month less five year age enrol . Study participation would point enrolment 60 day enrolment . Enrolment occur within 48 hour admission hospital . Enrolled participant randomise 1:1 Nitazoxanide ( NTZ ) placebo . Other treatment management per standard care describe admit hospital 's guideline ultimately decision responsibility name medical consultant . Stool sample collect point admission . Solicitation symptom review routinely collect medical data record participant 's medical record , supplement completion study specific diary card discharge . All participant follow day 7 enrolment ( telephone already discharge ) ascertain symptom occur intervening period . At day 30 60 enrolment clinical record review conduct participant ascertain health care attendance follow discharge .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>1 . Infant /child = &gt; 3 month &lt; 5 year age 2 . Infant/ child identify Indigenous legally responsible caregiver 3 . Infant /child been/will admit hospital acute infectious gastroenteritis ( opinion admit doctor and/or study doctor/nurse ) 4 . The legally responsible caregiver willing infant/ child participate study would expect comply requirement protocol , include able willing contact telephone discharge necessary 5 . The legally responsible caregiver willing allow party involve treatment child ( include general practitioner , paediatrician , hospital medical nursing staff , community clinic staff ) notify participation trial 6 . The legally responsible caregiver willing allow allow study team obtain vaccination history Australian Childhood Immunisation Register ( ACIR ) and/or local provider 7 . The legally responsible caregiver willing allow study team obtain interim medical history participant 's electronic medical record and/or participant 's general practitioner period enrolment study day 60 8 . Informed consent infant's/child 's participation study give legally responsible caregiver 1 . Admitted = &gt; 48 hour point enrolment 2 . Duration symptom great 14 day without apparent worsening symptom consistent acute pathology 3 . Presence grossly bloody diarrhoea 4 . Clinical suspicion noninfectious cause ( e.g . diagnose preexist medical condition predispose noninfectious diarrhoea , example inflammatory bowel disease ) except environmental enteropathy ) 5 . Contraindication study drug placebo ( e.g . allergy ) 6 . Diagnosis infection enteric pathogen antimicrobial treatment alternative antimicrobial standard care ( e.g . Shigella sp . ) 7 . Inability tolerate either oral nasogastric route ( e.g . ileus ) 8 . Clinical suspicion intestinal obstruction include bilious vomit 9 . Confirmed suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . 10 . Receipt 2 week immunosuppressant immune modify drug , ( e.g . prednisolone &gt; 0.5 mg/kg/day ) 11 . Receipt investigational drug/vaccine , drug use study , within 30 day prior receive first dose NTZ plan use study period , 1 month administration final dose NTZ 12 . Previously enrol trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>